Comparing Two Malaria Treatments in Africa
Author Information
Author(s): Yavo William, Faye Babacar, Kuete Thomas, Djohan Vincent, Oga Serge A, Kassi Richard R, Diatta Mariama, Ama Moor V, Tine Roger, Ndiaye Jean-Louis, Evi Jean-Bedel, Same-Ekobo Albert, Faye Oumar, Koné Moussa
Hypothesis
Dihydroartemisinin-piperaquine is as efficacious and safe as artemether-lumefantrine.
Conclusion
Dihydroartemisinin-piperaquine was as effective and well-tolerated as artemether-lumefantrine in treating uncomplicated falciparum malaria.
Supporting Evidence
- Both treatments were well tolerated with no serious adverse events reported.
- Recovery rates were 99.5% for dihydroartemisinin-piperaquine and 98.9% for artemether-lumefantrine.
- More than 90% of patients were free of fever or parasitaemia within 48 hours.
Takeaway
This study looked at two malaria treatments to see which one works better. Both treatments helped most people get better, but the new one is easier to take.
Methodology
A multicentric open randomized controlled trial comparing dihydroartemisinin-piperaquine and artemether-lumefantrine in patients with uncomplicated falciparum malaria.
Limitations
The study was limited to three countries and may not represent all populations with malaria.
Participant Demographics
Patients aged two years and above from Cameroon, Côte d'Ivoire, and Senegal.
Statistical Information
P-Value
0.538
Statistical Significance
p = 0.538
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website